New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2481-2491

  Agulnik, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Monoclonal antibody; Resistance; Squamous cell carcinoma of the head and neck; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PF 299; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ACNE; ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD PRESSURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHEMOTHOERAPY INDUCED ANEMIA; CHILL; DEHYDRATION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRY SKIN; DYSPHAGIA; DYSPNEA; EDEMA; ENZYME INHIBITION; ESOPHAGITIS; FATIGUE; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATURIA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LOOSE FECES; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION DERMATITIS; RADIATION INDUCED EMESIS; RECEPTOR BLOCKING; RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84867997123     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0159-2     Document Type: Review

References (79)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. BMJ. 2002;325:822-7.
3. ™. Head and neck cancers. Version 2.2011. http://www.nccn.org/professionals/physician-gls/PDF/head-and-neck.pdf. 2011.
4. Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2010;15:355-73.
5. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer. 2005;103:2435-46.
6. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-84.
7. Rubin Grandis J, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824-32.
8. Ang KK, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-6.
9. Psyrri A, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005;11:5856-62.
10. Dassonville O, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11:1873-8.
11. Chung CH, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170-6.
12. Temam S, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25:2164-70.
13. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5:180-6.
14. Chiang WF, et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas. Oral Oncol. 2008;44:270-6.
15. ® (cetuximab) injection, for intravenous infusion [package insert]. Distributed and marketed by Bristol-Myers Squibb Company, Princeton; Co-marketed by Eli Lilly and Company, Indianapolis; 2011.
16. Bonner JA, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78.
17. Bonner JA, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-8.
18. Ang KK, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol. 2011;29. Abstract 5500.
19. Pfister DG, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-8.
20. Langer CJ, Li JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2008;26. Abstract 6006.
21. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-54.
22. Vermorken JB, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-27.
23. Rozzi A, Lenci G, Corona M, et al. Weekly regimen of paclitaxel- carboplatin-cetuximab as first-line chemotherapy in patients with platinum-resistant recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN): results of a phase II study. Ann Oncol. 2010;21:viii323. Abstract 1035P.
24. Baselga J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-77.
25. Herbst RS, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578-87.
26. Vermorken JB, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-7.
27. Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics. 2010;4:173-85.
28. Moon C, Chae YK, Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood). 2010;235:907-20.
29. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695-709.
30. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14.
31. Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol. 2010;11:85-91.
32. Forastiere AA, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245-51.
33. Jacobs C, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257-63.
34. Gibson MK, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562-7.
35. Janinis J, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000;23:128-31.
36. Shin DM, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:1325-30.
37. Shin DM, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001;91:1316-23.
38. Jemal A, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
39. Wirth LJ, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010;21:342-7.
40. Rischin D, Spigel DR, Adkins D, et al. Panitumumab (pmab) regimen in second-line monotherapy (PRISM) in patients (pts) with recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN): interim safety analysis. Ann Oncol. 2010;21:viii323. Abstract 1036P.
41. Vermorken JB, Stohlmacher J, Davidenko I, et al. Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (pmab). Ann Oncol. 2010;21:viii12. Abstract LBA26.
42. Mateo C, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997;3:71-81.
43. Rojo F, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res. 2010;16:2474-82.
44. Crombet T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646-54.
45. Ramakrishnan MS, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1:41-8.
46. Babu KG, Viswanath L, Reddy BK, et al. An open-label, randomized study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study. J Clin Oncol. 2010;28. Abstract 5530.
47. Rodriguez MO, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9:343-9.
48. Gupta M, Madholia V, Gupta N, Bhowmik KT. Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck. J Clin Oncol. 2010;28. Abstract 5565.
49. Bleeker WK, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173:4699-707.
50. Bastholt L, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2007;85:24-8.
51. Machiels JP, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12:333-43.
52. Cohen EE, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-7.
53. Cohen EE, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11:8418-24.
54. Caponigro F, et al. A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs. 2008;19:739-44.
55. Hainsworth JD, et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer. 2009;115:2138-46.
56. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27. Abstract 6011.
57. Stewart JS, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27:1864-71.
58. Herchenhorn D, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2010;78:696-702.
59. Hayes DN, Raez LE, Sharma AK, et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. J Clin Oncol. 2010;28. Abstract 5580.
60. Soulieres D, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
61. Siu LL, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25:2178-83.
62. Kondo N, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep. 2010;23:957-63.
63. Harrington KJ, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1100-7.
64. Harrington KJ, Berrier A, Robinson M, et al. Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2010;28. Abstract 5505.
65. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2006;24. Abstract 5568.
66. Sok JC, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006;12:5064-73.
67. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010;16:2489-95.
68. Erjala K, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006;12:4103-11.
69. Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702-11.
70. Yamamoto N, et al. A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib or gefitinib. Poster presented at: the Annual Meeting of the American Society of Clinical Oncology; 4-8 June, 2011; Chicago, IL. Abstract 7524.
71. Seiwert TY, Fayette J, Del Campo JM, et al. A randomized, open-label phase II study of afatinib (BIBW 2992) versus cetuximab in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC) after failure of platinum-containing therapy with a cross-over for progressing patients. Presented at: the 35th European Society for Medical Oncology (ESMO); 8-12 October, 2010; Milan. Abstract 1010PD.
72. Engelman JA, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67:11924-32.
73. Siu LL, et al. Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2011;29. Abstract 5561.
74. Amornphimoltham P, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005;65:9953-61.
75. Aissat N, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2008;62:305-13.
76. Neuchrist C, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck. 2003;25:464-74.
77. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434-40.
78. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:624-30.
79. Cohen EE, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247-57.